NO20005031L - Kinolin-4-yl-derivater II - Google Patents
Kinolin-4-yl-derivater IIInfo
- Publication number
- NO20005031L NO20005031L NO20005031A NO20005031A NO20005031L NO 20005031 L NO20005031 L NO 20005031L NO 20005031 A NO20005031 A NO 20005031A NO 20005031 A NO20005031 A NO 20005031A NO 20005031 L NO20005031 L NO 20005031L
- Authority
- NO
- Norway
- Prior art keywords
- hydrogen
- lower alkyl
- pyrrolidin
- halogen
- amino
- Prior art date
Links
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- BXAIQPPVOCFPQA-UHFFFAOYSA-N 1-aminopyrrolidin-3-ol Chemical compound NN1CCC(O)C1 BXAIQPPVOCFPQA-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000021617 central nervous system development Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- -1 hydroxy, amino Chemical group 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000007996 neuronal plasticity Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- HVVNJUAVDAZWCB-UHFFFAOYSA-N prolinol Chemical compound OCC1CCCN1 HVVNJUAVDAZWCB-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Foreliggende oppfinnelse angår forbindelser med den generelle formel. hvor. R1 er hydrogen, lavere alkyl, lavere alkoksy, hydroksy, amino, nitro,. cyano, lavere alkyl-amino, di-lavere alkyl-amino eller halogen;. Rer hydrogen, lavere alkyl, amino, pyrrolidin-3-ol, pyrrolidin-2-yl-metanol eller -NHCHCHROH;. er hydrogen eller halogen;. R er hydrogen, lavere alkyl eller -CHOH;. n er 1 eller 2;. og farmasøytisk akseptable syreaddisjonssalter derav.Forbindelser ifølge foreliggende oppfinnelse er NMDA(N-metyl-D-aspartat)-reseptor subtypeselektive blokkere, som har en nøkkelfunksjon i modulering av neuronal aktivitet og plastisitet i medierende prosesser som ligger bak utvikling av CNS så vel som læring og hukommelsesdannelse.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99120131 | 1999-10-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20005031D0 NO20005031D0 (no) | 2000-10-06 |
| NO20005031L true NO20005031L (no) | 2001-04-09 |
Family
ID=8239160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005031A NO20005031L (no) | 1999-10-08 | 2000-10-06 | Kinolin-4-yl-derivater II |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6339093B1 (no) |
| EP (1) | EP1090917B1 (no) |
| JP (1) | JP3385318B2 (no) |
| KR (1) | KR100398562B1 (no) |
| CN (1) | CN1162424C (no) |
| AR (1) | AR032601A1 (no) |
| AT (1) | ATE313538T1 (no) |
| AU (1) | AU777881B2 (no) |
| BR (1) | BR0004709A (no) |
| CA (1) | CA2322309C (no) |
| DE (1) | DE60024947T2 (no) |
| DK (1) | DK1090917T3 (no) |
| EG (1) | EG23872A (no) |
| ES (1) | ES2254095T3 (no) |
| HR (1) | HRP20000652A2 (no) |
| HU (1) | HUP0003938A2 (no) |
| ID (1) | ID27526A (no) |
| IL (1) | IL138916A0 (no) |
| MA (1) | MA26753A1 (no) |
| MX (1) | MXPA00009771A (no) |
| NO (1) | NO20005031L (no) |
| NZ (1) | NZ507303A (no) |
| PE (1) | PE20010660A1 (no) |
| PL (1) | PL343057A1 (no) |
| TR (1) | TR200002893A3 (no) |
| ZA (1) | ZA200005447B (no) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| US7375136B2 (en) | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
| US6831087B2 (en) | 2001-11-09 | 2004-12-14 | Hoffmann-La Roche Inc. | Pyridine substituted isoquinoline derivatives |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| MY146992A (en) * | 2007-06-18 | 2012-10-15 | Richter Gedeon Nyrt | Sulfonyl-quinoline derivatives |
| EA201070077A1 (ru) * | 2007-06-29 | 2010-08-30 | Эмори Юниверсити | Антагонисты nmda-рецепторов с нейропротективным действием |
| EP2215074B1 (en) * | 2007-09-27 | 2014-02-19 | The United States of America, as Represented by the Secretary, Department of Health and Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| JP7071917B2 (ja) | 2015-12-09 | 2022-05-19 | カデント セラピューティクス,インコーポレーテッド | ヘテロ芳香族nmda受容体モジュレーターおよびその使用 |
| DK3452465T3 (da) * | 2016-05-04 | 2021-02-08 | Genoscience Pharma | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme |
| US11274107B2 (en) | 2016-12-22 | 2022-03-15 | Cadent Therapeutics, Inc. | NMDA receptor modulators and uses thereof |
| AR115905A1 (es) | 2018-08-03 | 2021-03-10 | Cadent Therapeutics Inc | 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1-il)-2-oxoetil)-3,7-dihidro-4h-pirrolo[2,3-d]pirimidin-4-ona como modulador de los receptores de nmda |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8409745D0 (en) * | 1984-04-14 | 1984-05-23 | Beecham Group Plc | Active compounds |
| US4560692A (en) * | 1984-07-18 | 1985-12-24 | Hoffmann-La Roche Inc. | 4-Piperidino-2-phenylquinolines |
| GB8716972D0 (en) * | 1987-07-17 | 1987-08-26 | Pfizer Ltd | Treatment of cardiac arrhythmias |
| JPH0262875A (ja) | 1988-05-23 | 1990-03-02 | Wakunaga Pharmaceut Co Ltd | 新規イソインドリン誘導体 |
| US4992448A (en) * | 1989-10-24 | 1991-02-12 | Hoechst-Roussel Pharmaceuticals Inc. | Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders |
| US5304554A (en) * | 1990-04-27 | 1994-04-19 | Emory University | 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation |
| GB9203798D0 (en) * | 1992-02-21 | 1992-04-08 | Fujisawa Pharmaceutical Co | Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
| GB9305644D0 (en) * | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
| US5567718A (en) * | 1994-08-11 | 1996-10-22 | Hoechst Marion Roussel Inc. | 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors |
| ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
-
2000
- 2000-09-26 US US09/669,648 patent/US6339093B1/en not_active Expired - Fee Related
- 2000-09-29 CN CNB001290843A patent/CN1162424C/zh not_active Expired - Fee Related
- 2000-10-02 ES ES00121561T patent/ES2254095T3/es not_active Expired - Lifetime
- 2000-10-02 EP EP00121561A patent/EP1090917B1/en not_active Expired - Lifetime
- 2000-10-02 AT AT00121561T patent/ATE313538T1/de not_active IP Right Cessation
- 2000-10-02 DE DE60024947T patent/DE60024947T2/de not_active Expired - Lifetime
- 2000-10-02 DK DK00121561T patent/DK1090917T3/da active
- 2000-10-03 PE PE2000001045A patent/PE20010660A1/es not_active Application Discontinuation
- 2000-10-03 HR HR20000652A patent/HRP20000652A2/hr not_active Application Discontinuation
- 2000-10-03 NZ NZ507303A patent/NZ507303A/xx unknown
- 2000-10-04 MA MA26080A patent/MA26753A1/fr unknown
- 2000-10-04 TR TR2000/02893A patent/TR200002893A3/tr unknown
- 2000-10-04 JP JP2000304354A patent/JP3385318B2/ja not_active Expired - Fee Related
- 2000-10-04 ID IDP20000858D patent/ID27526A/id unknown
- 2000-10-04 EG EG20001265A patent/EG23872A/xx active
- 2000-10-04 CA CA002322309A patent/CA2322309C/en not_active Expired - Fee Related
- 2000-10-05 MX MXPA00009771A patent/MXPA00009771A/es active IP Right Grant
- 2000-10-05 IL IL13891600A patent/IL138916A0/xx unknown
- 2000-10-05 ZA ZA200005447A patent/ZA200005447B/xx unknown
- 2000-10-05 AR ARP000105238A patent/AR032601A1/es not_active Application Discontinuation
- 2000-10-06 NO NO20005031A patent/NO20005031L/no not_active Application Discontinuation
- 2000-10-06 HU HU0003938A patent/HUP0003938A2/hu unknown
- 2000-10-06 BR BR0004709-0A patent/BR0004709A/pt not_active Application Discontinuation
- 2000-10-06 AU AU64100/00A patent/AU777881B2/en not_active Ceased
- 2000-10-07 KR KR10-2000-0059049A patent/KR100398562B1/ko not_active Expired - Fee Related
- 2000-10-09 PL PL00343057A patent/PL343057A1/xx not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20005031L (no) | Kinolin-4-yl-derivater II | |
| NO20023218L (no) | 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer | |
| NO20021328L (no) | Pyrazolopyrimidier som terapeutiske midler | |
| NO933434L (no) | Piperidinderivater, deres fremstilling og anvendelse | |
| FI953968A0 (fi) | Antraniiliset happojohdannaiset | |
| MXPA02003977A (es) | Inhibidores de adhesion de celula mediada por al°2. | |
| NO20045369L (no) | Nye, substituerte sulfamatanticonvulsivaderivater | |
| NO991761L (no) | Nye piperidin-kotokarbonsyre-derivater, deres fremstilling og anvendelse | |
| DE60305514D1 (de) | Neue verwendung von benzothiazolderivaten | |
| NZ514487A (en) | Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands | |
| HUP0400246A2 (hu) | 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra | |
| TW200504085A (en) | Derivatives of [2-(8,9-dioxo-2, 6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of use thereof | |
| NO20023161L (no) | Substituerte piperidiner, legemidler inneholdende disse forbindelser og fremgangsmåter for fremstilling av dem | |
| WO2002008219A3 (en) | 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | |
| NO20044571L (no) | Isokinolinderivater | |
| TR200403436T2 (tr) | Kristalin 1-metilkarbapenem türevleri. | |
| NO20022232L (no) | Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII | |
| NO20032261L (no) | Medisinske preparater | |
| NO20050087L (no) | N-benzoylureido-kanelsyrederivater, fremgangsmate for fremstilling og anvendelse av disse | |
| NO20001781L (no) | 3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse | |
| NO20051900L (no) | Kinazolinderivater som SRC tyrosin kinase inhibitorer | |
| NO20022123L (no) | Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII | |
| NO20023001L (no) | Substituerte piperazinderivater som MTP inhibitorer | |
| NO20051901L (no) | Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger | |
| CA2399818A1 (en) | Preventive and therapeutic medicament for gastroesophageal reflux disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |